All News

podcast logo

RheumNow Podcast – Rheumatology Burnout (1.29.2021)

d Jack Cush, MD

Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.

Read Article
infx.pneumonia.jpg

Calculating Serious Infection Risk in IMID Patients

d Jack Cush, MD

Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection (SIE) in those starting biologic DMARD (bDMARD) treatment. From this large dataset, researchers developed a simple prediction model to estimate future infection risk that may inform shared decision-making in individual patients.

Read Article
Download our latest resource--Televideo Joint Exam Checklist. https://t.co/XnyCW2eak8

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow podcast is now up--listen in on SoundCloud, RheumNow or Apple/Android car play. Rheumatology Burnout?--Dr. Cush reviews the top articles from the week of 1/29/21. https://t.co/HiX7qMFU6b https://t.co/KbaZ6XjHG6

Links:

Dr. John Cush RheumNow ( View Tweet)
Calculating Serious Infection Risk in IMID Patients Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection in those starting biologic DMARD treatment. Read more: https://t.co/i2GwiCvCx6 https://t.co/9sZ79LyZ7u

Links:

Dr. John Cush RheumNow ( View Tweet)
High Placebo Responses in SLE Trials A systematic review in randomized controlled trials (RCTs) of non-renal, non-neuropsychiatric systemic lupus erythematosus (SLE) patients showing unexpectedly high placebo responses. Read more: https://t.co/zUPsVFEz4n https://t.co/Gk7ke4hBwY

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic Podcast for the week of Jan 29 - Pearls from Practice This wk: Arthritis &Crohn's Rhabdo or Not Dadgummit, Where's Waldos COVID Vaccine? "I Don't Know" A Tale of Two Gouts https://t.co/7ndYSOgh5R or listen on iTunes https://t.co/FHJv01AAbC https://t.co/780P7Bdw8F

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is up - Rheumatology Burnout (1.29.2021) - Vaccine #s, Colchicine in COVID, Rheums #2 in Burnout? Endometriosis & RA risk, Comorbidity as predictors. https://t.co/HiX7qMFU6b or listen on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>> https://t.co/0BfqGhxgQj https://t.co/j9nHMs4C6d

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus Nephritis Despite Low Level Proteinuria https://t.co/awxvsvwGTg https://t.co/e6DV6sfiN5

Links:

Dr. John Cush RheumNow ( View Tweet)
2016 Deloitte report on top 10 healthcare innovations (Spot on!): 1 Next gen sequencing 2 3-D printing 3 AI 4 Immunotherapy 5 Point of care diagnostics 6 virtual reality 7 social media for Pts 8 Biosensors/trackers 9 Telehealth 10 Convenient care https://t.co/yWaqzM9pFC

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/NmDXrTPGXq

Links:

Dr. John Cush RheumNow ( View Tweet)
Several studies have shown that Xray progression has lessened in recent yrs - presumeably from more aggressive Rx by Rheums! Still - Predictors of Xray long term damage = high ESR/CRP, baseline xray damage, -CCP/RF positivity https://t.co/2iaMiaquEV https://t.co/cgEP4QBvL4

Links:

Dr. John Cush RheumNow ( View Tweet)

JAK Inhibitor Misses Endpoint in Safety Study. Now What? Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class. https://t.co/EPVdAdPP37 https://t.co/Box5NaxsKV

Links:

Dr. John Cush RheumNow ( View Tweet)
News: #COVID19 risk may be reduced with #biologics and #JAKinhibitors, but increased with #glucocorticoids, Italian researchers report in @ArthritisRes https://t.co/zIef2aNCns

Links:

Medicine Matters rheumatology Rheum_Matters ( View Tweet)

SELECT-PsA2, UPA vs PLBO in refractory PsA, @ARD_BMJ Better ACR20 (57% vs 24% PLBO, NNT~3) and ACR50 (32% vs 5% PLBO, NNT~4). Decent PASI 90 (30% vs 6%, NNT~4) Similar adverse events to RA pop. Nice to have another option, esp in refractory dx! https://t.co/Zz2WYqswT2
Mike Putman EBRheum ( View Tweet)
My #rheumatology clinics now inundated with patient questions re: #CovidVaccine. I'm looking forward to new #CovidVaccine Guidance expected from the newly-convened #ACR Task Force, forthcoming on February 11th.

Jeffrey Curtis RADoctor ( View Tweet)

Is there such a thing as "Preclinical Lupus" - half to 2/3 of SLE pts had + serologies up to 9 yrs before the Dx @KDAO2011 @UTSWIMchief @UTSWIMchief https://t.co/ThpKjZEG2v

Dr. John Cush RheumNow ( View Tweet)
The new ACR/EULAR SLE Classification Criteria 2019 with weighted criteria - need to be ANA+ and have 10 points @UTSWIMchief @UTSWInternalMed https://t.co/TwyUbEOCg2
Dr. John Cush RheumNow ( View Tweet)
UT Southwestern Grand Rounds w/ Dr. Kathyrn Dao @KDAO2011 - lecturing on lupus. Showing that the population rate of ANA has increased over time - NHANES shows 44 million in the USA have +ANA! @UTSWInternalMed @UTSWIMchief https://t.co/qU5gzuAD9j
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Dadgummit, Where's Waldo's COVID Vaccine? My rant on the COVID vaccine unavailability, and what we can - and can't - tell patients. https://t.co/VKrDgvuXqt https://t.co/zuNe8lEaR4

Links:

Dr. John Cush RheumNow ( View Tweet)
×